menu
    • menu
    [{"orgOrder":0,"company":"XenoTherapeutics","sponsor":"Essa Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Masofaniten","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase II","graph3":"XenoTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XenoTherapeutics \/ XenoTherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"XenoTherapeutics \/ XenoTherapeutics"},{"orgOrder":0,"company":"XenoTherapeutics","sponsor":"Joseph M. Still Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Realskin","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"XenoTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Dressing","sponsorNew":"XenoTherapeutics \/ Joseph M. Still Research Foundation","highestDevelopmentStatusID":"10","companyTruncated":"XenoTherapeutics \/ Joseph M. Still Research Foundation"},{"orgOrder":0,"company":"XenoTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Xeno-Skin","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"XenoTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XenoTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"XenoTherapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by XenoTherapeutics

    Menu

    XenoTherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            XenoTherapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            XenoTherapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Masofaniten,Enzalutamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Essa Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            ESSA Pharma Announces Definitive Agreement to be Acquired by XenoTherapeutics

                            Details : XenoTherapeutics is acquiring ESSA Pharma to expand its pipeline by including, prostate cancer therapy EPI-7386 (masofaniten), a next-generation androgen receptor inhibitor.

                            Product Name : EPI-7386

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 14, 2025

                            Lead Product(s) : Masofaniten,Enzalutamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Essa Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            XenoTherapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            XenoTherapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Realskin

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase III

                            Sponsor : Joseph M. Still Research Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Burn Wounds as an Alternative to Auto...

                            Details : Realskin is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Burns Degree Third.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 25, 2024

                            Lead Product(s) : Realskin

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase III

                            Sponsor : Joseph M. Still Research Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            XenoTherapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            XenoTherapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xeno-Skin

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            XenoTherapeutics Completes First Cohort of Patients in First US Clinical Trial of Live-Cell Xenotransplant

                            Details : XenoTherapeutics has completed the first of two patient cohorts in the company’s Phase I trial of Xeno-Skin™, first-in-human, live-cell xenotransplant to treat severe and extensive burn wounds. As a result, the U.S. FDA has agreed to permit accelerat...

                            Product Name : Xeno-Skin

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 05, 2020

                            Lead Product(s) : Xeno-Skin

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth